NMNAT1 anticorps (AA 56-279)

N° du produit ABIN7875763

Cet anticorps anti-NMNAT1 Polyclonal Lapin (ABIN7875763) détecte spécifiquement NMNAT1 dans WB, ELISA, IHC, IF, FACS et ICC. L’anticorps est réactif avec des échantillons de Humain, Souris et Rat.

Aperçu rapide pour NMNAT1 anticorps (AA 56-279) (ABIN7875763)

Antigène: NMNAT1 (Nicotinamide Nucleotide Adenylyltransferase 1 (NMNAT1))

Reactivité: Humain, Souris, Rat

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp NMNAT1 est non-conjugé

Application: Western Blotting (WB), ELISA, Immunohistochemistry (IHC), Immunofluorescence (IF), Flow Cytometry (FACS), Immunocytochemistry (ICC)

Détail du produit anti-NMNAT1 anticorps

Épitope: AA 56-279

Fonction: NMNAT1 Antibody / Nicotinamide mononucleotide adenylyltransferase 1

Purification: Immunogen affinity purified

Immunogène: E.coli-derived human NMNAT1 recombinant protein (Position: K56-T279) was used as the immunogen for the NMNAT1 antibody.

Isotype: IgG

Information d'application

Indications d'application: Optimal dilution of the NMNAT1 antibody should be determined by the researcher.

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Reconstitution: Adding 0.2 mL of distilled water will yield a concentration of 500 μg/mL

Buffer: Each vial contains 4 mg Trehalose, 0.9 mg NaCl, 0.2 mg Na2HPO4.

Stock: 4 °C,-20 °C

Stockage commentaire: After reconstitution, the NMNAT1 antibody can be stored for up to one month at 4oC. For long-term, aliquot and store at -20oC. Avoid repeated freezing and thawing.

Détails sur NMNAT1

Antigène: NMNAT1 (Nicotinamide Nucleotide Adenylyltransferase 1 (NMNAT1))

Autre désignation: NMNAT1

Sujet: NMNAT1 antibody targets Nicotinamide mononucleotide adenylyltransferase 1, a key nuclear enzyme in the NAD+ biosynthetic pathway. NMNAT1 catalyzes the conversion of nicotinamide mononucleotide (NMN) and ATP to NAD+ and pyrophosphate, representing the final step in the salvage pathway that maintains cellular NAD+ levels. This metabolite is vital for redox reactions, DNA repair, and signaling processes involving sirtuins and PARPs. The NMNAT family includes three isoforms-NMNAT1 (nuclear), NMNAT2 (cytoplasmic/golgi), and NMNAT3 (mitochondrial)-each serving tissue-specific and compartment-specific functions. Among them, NMNAT1 localizes to the nucleus and associates with DNA repair machinery, chromatin remodelers, and transcriptional regulators.

Genetic studies have established that NMNAT1 is essential for embryonic viability and neuronal survival. Mutations in the NMNAT1 gene cause Leber congenital amaurosis type 9 (LCA9), a severe inherited retinal dystrophy characterized by early-onset vision loss due to impaired photoreceptor maintenance. The enzyme's role in maintaining nuclear NAD+ pools underlies its protective effects against oxidative and genotoxic stress. Beyond ocular disease, NMNAT1 contributes to genomic stability by supporting PARP-dependent DNA damage responses. Cellular NAD+ depletion impairs repair efficiency, highlighting NMNAT1 as a therapeutic target for age-related degeneration and metabolic disorders.

In neurobiology, NMNAT1 has gained attention for its neuroprotective potential. Experimental models demonstrate that increasing NMNAT1 expression can delay axonal degeneration following injury, a phenomenon known as Wallerian degeneration slow (WldS). This protective capacity likely arises from preserved nuclear NAD+ synthesis, influencing downstream survival pathways. Moreover, NMNAT1 coordinates with sirtuin-1 (SIRT1) to regulate gene expression and chromatin structure through histone deacetylation mechanisms. Disruption of this balance is linked to premature cellular aging and retinal degeneration.

The NMNAT1 antibody is a critical reagent for probing NAD+ metabolism, DNA repair, and neuroprotection pathways. Researchers use it for western blotting, immunocytochemistry, and immunohistochemistry to detect endogenous NMNAT1 across cell types. Its nuclear localization pattern provides a distinct marker for studying NAD+ biosynthesis compartmentalization. In clinical research, NMNAT1 expression is analyzed in retinal tissues, cancer cell lines, and aging models to evaluate metabolic resilience. The antibody's specificity allows discrimination between NMNAT1 and its cytoplasmic and mitochondrial isoforms, ensuring accurate interpretation of NAD+-related experiments.

Because of its central role in redox regulation, NMNAT1 represents a molecular intersection between energy metabolism, genome integrity, and cellular stress responses. By targeting this enzyme, the NMNAT1 antibody supports studies into retinal dystrophy, neurodegeneration, and therapeutic NAD+ augmentation strategies. NSJ Bioreagents provides a validated NMNAT1 antibody optimized for western blot and immunohistochemical assays, enabling precise analysis of nuclear NAD+ metabolism and DNA repair pathways.

UniProt: Q9HAN9